Attached files

file filename
EX-99.2 - PRESS RELEASE, DATED JANUARY 28, 2021 - Biotech Acquisition Coea134164ex99-2_biotechacq.htm
EX-99.1 - PRESS RELEASE, DATED JANUARY 25, 2021 - Biotech Acquisition Coea134164ex99-1_biotechacq.htm
EX-10.5 - SPONSOR WARRANTS PURCHASE AGREEMENT, DATED JANUARY 25, 2021 BY AND BETWEEN THE C - Biotech Acquisition Coea134164ex10-5_biotechacq.htm
EX-10.3 - REGISTRATION RIGHTS AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COMPAN - Biotech Acquisition Coea134164ex10-3_biotechacq.htm
EX-10.2 - INVESTMENT MANAGEMENT TRUST AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN TH - Biotech Acquisition Coea134164ex10-2_biotechacq.htm
EX-10.1 - LETTER AGREEMENT, DATED JANUARY 25, 2021, BY AND AMONG THE COMPANY, ITS OFFICERS - Biotech Acquisition Coea134164ex10-1_biotechacq.htm
EX-4.1 - WARRANT AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COMPANY AND CONTIN - Biotech Acquisition Coea134164ex4-1_biotechacq.htm
EX-3.1 - AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION - Biotech Acquisition Coea134164ex3-1_biotechacq.htm
EX-1.1 - UNDERWRITING AGREEMENT, DATED JANUARY 25, 2021 BY AND BETWEEN THE COMPANY AND CA - Biotech Acquisition Coea134164ex1-1_biotechacq.htm
8-K - CURRENT REPORT - Biotech Acquisition Coea134164-8k_biotechacq.htm

Exhibit 10.4

 

BIOTECH ACQUISITION COMPANY

545 West 25th Street, 20th Floor

New York, NY 10001

 

January 25 , 2021

Biotech Sponsor LLC

545 West 25th Street, 20th Floor

New York, NY 10001

 

Re:Administrative Services Agreement

 

Ladies and Gentlemen:

 

This letter agreement by and between Biotech Acquisition Company., a Cayman Islands exempted company (the “Company”), and Biotech Sponsor LLC, dated as of the date hereof, will confirm our agreement that, commencing on the date the securities of the Company are first listed on The Nasdaq Capital Market LLC (the “Listing Date”), pursuant to a Registration Statement on Form S-1 and prospectus filed with the Securities and Exchange Commission (the “Registration Statement”) and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation (in each case as described in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”):

 

(i) ITHAX Acquisition Sponsor LLC, the Company’s sponsor, shall make available, or cause to be made available, to the Company, at 545 West 25th Street, 20th Floor, New York, NY 10001 (or any successor location of Biotech Sponsor LLC), office space and administrative and support services. In exchange therefor, the Company shall pay Biotech Sponsor LLC the sum of $10,000 per month on the Listing Date and continuing monthly thereafter until the Termination Date; and

 

(ii) Biotech Sponsor LLC hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind as a result of, or arising out of, this letter agreement (each, a “Claim”) in or to, and any and all right to seek payment of any amounts due to it out of, the trust account established for the benefit of the public shareholders of the Company and into which substantially all of the proceeds of the Company’s initial public offering will be deposited (the “Trust Account”), and hereby irrevocably waives any Claim it may have in the future, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.

 

This letter agreement constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby.

 

This letter agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.

 

No party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.

 

 

 

 

This letter agreement constitutes the entire relationship of the parties hereto, and any litigation between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York, without giving effect to its choice of laws principles.

 

This letter agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same letter agreement.

 

[Signature Page Follows]

 

 

 

 

  Very truly yours,
   
  BIOTECH ACQUISITION COMPANY
     
  By:  /s/ Michael Shleifer
    Name: Michael Shleifer
    Title: Chief Executive Officer

 

AGREED TO AND ACCEPTED BY:  
   
BIOTECH SPONSOR LLC  
       
By: /s/ Michael Shleifer  
  Name: Michael Shleifer  
  Title: Chairman of the Board of Directors  

 

[Signature Page to Administrative Services Agreement]